Crestor and route of elimination

Rosuvastatin Pathway, Pharmacokinetics - PharmGKB

Rosuvastatin Pathway, Pharmacokinetics - PharmGKB Brilique 60 mg twice daily is the recommended dose when an extended treatment is required for patients with a history of MI of at least one year and a hh risk of an atherothrombotic event (see section 5.1). The main pathway of elimination is ABC transporter mediated biliary excretion. The pharmacokinetics of individual statin drugs are influenced by their.

Oral Absorption, Intestinal Metabolism <strong>and</strong> Human Oral. - InTech

Oral Absorption, Intestinal Metabolism and Human Oral. - InTech 5 mg, 10 mg, 20 mg, 40 mg tablets Rosuvastatin is a potent inhibitor of HMG-Co A reductase, an enzyme that catalyzes the conversion of HMG-Co A to mevalonic acid, an early and rate-limiting step in cholesterol biosynthesis. Elimination across the intestine Fg and liver Fh can be estimated. The transcellular pathway is the major route of absorption for most of drug molecules. transport of E-3-S, but not rosuvastatin, is pH-sensitive in intestinal.

Rosuvastatin - DrugBank

Rosuvastatin - DrugBank Individual plans may vary and formulary information changes. Rosuvastatin belongs to a class of medications ed statins and is used. Route of elimination, Rosuvastatin is not extensively metabolized;.

Crestor and route of elimination:

Rating: 89 / 100

Overall: 100 Rates